<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01817738</url>
  </required_header>
  <id_info>
    <org_study_id>CV-9104-004</org_study_id>
    <nct_id>NCT01817738</nct_id>
  </id_info>
  <brief_title>Trial of RNActive®-Derived Prostate Cancer Vaccine in Metastatic Castrate-refractory Prostate Cancer</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Phase I/II Trial of RNActive®-Derived Cancer Vaccine (CV9104) in Asymptomatic or Minimally Symptomatic Patients With Metastatic Castrate-refractory Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CureVac AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CureVac AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the new RNActive®-derived prostate cancer
      vaccine CV9104 prolongs survival in patients with asymptomatic or minimally symptomatic
      metastatic prostate cancer that is castrate resistant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is the first clinical study with the new prostate cancer vaccine CV9104. This
      vaccine is composed of 6RNActive®-based compounds, each encoding for an antigen that is
      overexpressed in prostate cancer compared to healthy tissues. RNActive®-based vaccines are a
      novel class of vaccines based on messenger RNA.

      The study is a double-blind randomized placebo-controlled phase I/II trial in men with
      asymptomatic- minimally symptomatic metastatic castrate-refractory prostate cancer.

      The phase 1 (safety lead- in) part of the trial has the primary objective to assess the
      safety of CV9104 and to determine the dose for the randomized phase II part.

      The primary objective of the phase II part is to compare overall survival in patients treated
      with CV9104 compared to patients treated with placebo.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Follow up period after primary analysis was prematurely stopped because more mature data will
    not impact the study outcome
  </why_stopped>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I (Safety Lead-In): Occurrence of dose-limiting toxicity (DLT) during the first 4 weeks of treatment (after administration of 3 vaccinations and after a 1 week observation period</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Safety Lead in Portion:
Patients will receive CV9104 at a starting dose of 1920 µg in weeks 1, 2 and 3. Safety lead-in patients will be observed for DLTs until 1 week after Vaccination 3 (week 4). In case no DLTs will be observed vaccinations will continue in weeks 5, 7, 9, 12, 15, 18 and 24, then every 6 weeks for up to 12 months after the first vaccination and then every 3 months thereafter until one of the criteria for study treatment discontinuation is met</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II (Randomised Portion): Overall Survival from time of randomisation- up to 3.5-4 years.</measure>
    <time_frame>Overall survival will be assessed during the lifetime of the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival from date of randomisation</measure>
    <time_frame>Every 3 months for up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival from start of first subsequent systemic therapy</measure>
    <time_frame>Every 6 months until 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change to maximal and to minimal PSA from baseline and before start of first subsequent systemic cancer therapy and from start of first systemic therapy to end of first subsequent systemic therapy</measure>
    <time_frame>Every 3 months up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cellular and humoral immune response rate against the 6 antigens encoded by CV9104</measure>
    <time_frame>Immune responses will be assessed at baseline, in week 6 and week 24 after start of vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to symptom progression based on FACT P score and subscores</measure>
    <time_frame>Assessments at baseline, weeks 5, 9,18, 24 and every 3 months for up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change and area under the curve from baseline EQ-5D score and pain sub-score</measure>
    <time_frame>Assessments at baseline, weeks 5, 9,18, 24 and thereafter every 3 months for up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival from randomisation until second progression on first subsequent therapy</measure>
    <time_frame>Every 3 and 6 months up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">197</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>CV9104</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CV9104 intradermal injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo intradermal injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CV9104</intervention_name>
    <description>Intradermal injection of CV9104</description>
    <arm_group_label>CV9104</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intradermal injection of placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Male, age ≥18 years

          2. Histologically confirmed castrate refractory metastatic adenocarcinoma of the prostate
             with progressive disease after surgical castration or during androgen suppression
             therapy including a GNRH agonist or antagonist and after at least 1 additional
             anti-hormonal manipulation; and serum testosterone level of &lt; 50 ng/dL or &lt; 1.7 nmol/L

             Progression will be confirmed either

               -  radiologically or

               -  by 2 consecutive rises of PSA, measured at least 1 week apart, resulting at least
                  in a 50% increase over the nadir and a PSA &gt; 2 ng/mL.

               -  An antiandrogen withdrawal response must have been excluded after discontinuation
                  of antiandrogen therapy for at least 6 weeks.

          3. Metastatic disease confirmed by imaging

          4. ECOG performance status 0 or 1

        Key Exclusion Criteria:

          1. Previous immunotherapy for PCA (e.g. sipuleucel-T [Provenge®], experimental cancer
             vaccines or ipilimumab [Yervoy®]).

          2. Treatment with any investigational anticancer agents within 4 weeks prior to first
             dose of study drug

          3. Systemic treatment with immunosuppressive agents

          4. Active skin disease (atopic eczema, psoriasis) in the areas for vaccine injection
             (upper arms or thighs) preventing the administration of i.d. injections into areas of
             healthy skin.

          5. History of or current autoimmune disorders

          6. Primary or secondary immune deficiency.

          7. Seropositive for human immunodeficiency virus, hepatitis B virus (except after
             hepatitis B vaccination) or hepatitis C virus infection.

          8. Symptomatic congestive heart failure (New York Heart Association 3 or 4), unstable
             angina pectoris or myocardial infarction, significant cardiac arrhythmia, history of
             stroke or transient ischemic attack, all within 6 months prior to enrolment or severe
             hypertension according to WHO criteria or uncontrolled hypertension at the time of
             enrolment (systolic blood pressure ≥ 180 mm Hg)´

          9. Previous chemotherapy for metastatic PCA.

         10. Previous anti-hormonal treatment with abiraterone or any other investigational
             anti-hormonal treatment.

         11. Cancer-related pain requiring opioid narcotics within 28 days before enrolment or an
             average pain score of &gt; 3 on a visual analogue scale.

         12. Presence of visceral metastases.

         13. History of other malignancies other than PCA over the last 5 years (except basal cell
             carcinoma of the skin).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnulf Stenzl, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Tübingen; Dept. of Urology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Krajská zdravotní, a.s. - Nemocnice Chomutov, o.z.Onkologické oddělení</name>
      <address>
        <city>Chomutov</city>
        <zip>430 12</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultní nemocnice Olomouc, Urologická klinika</name>
      <address>
        <city>Olomouc</city>
        <zip>779 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiscan, a.s, Oddělení klinické a radiační onkologie</name>
      <address>
        <city>Pardubice</city>
        <zip>532 03</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomayerova nemocnice, Urologické oddělení</name>
      <address>
        <city>Praha</city>
        <zip>140 59</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krajská zdravotní, a.s. - Masarykova nemocnice Ústí nad Labem</name>
      <address>
        <city>Usti nad Labem</city>
        <zip>401 13</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Aachen Klinik für Urologie</name>
      <address>
        <city>Aachen</city>
        <zip>D-52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum Am Urban Klinik für Urologie</name>
      <address>
        <city>Berlin</city>
        <zip>D-10967</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinisches Zentrum Friedensplatz</name>
      <address>
        <city>Bonn</city>
        <zip>53111</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Dresden Klinik und Poliklinik für Urologie</name>
      <address>
        <city>Dresden</city>
        <zip>D-01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chirurgische Universitätsklinik Freiburg Klinik für Urologie</name>
      <address>
        <city>Freiburg</city>
        <zip>D-79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologikum Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>22081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationales Zentrum für Tumorerkrankungen Medizinische Onkologie</name>
      <address>
        <city>Heidelberg</city>
        <zip>D-69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologie am Nordplatz</name>
      <address>
        <city>Leipzig</city>
        <zip>04105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMM Universitätsmedizin Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr.schulze</name>
      <address>
        <city>Marklleeberg</city>
        <zip>04416</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologische Klinik und Poliklinik der Technischen Universität München Klinikum Rechts der Isar</name>
      <address>
        <city>Munich</city>
        <zip>D-81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster Klinik und Poliklinik für Urologie</name>
      <address>
        <city>Münster</city>
        <zip>D-48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Studienpraxis für Urologie</name>
      <address>
        <city>Nürtingen</city>
        <zip>D-72622</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ortenau Klinikum Urologie und Kinderurologie</name>
      <address>
        <city>Offenburg</city>
        <zip>77654</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologische Klinik Dr. Castingius München</name>
      <address>
        <city>Planegg</city>
        <zip>82152</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Urologie</name>
      <address>
        <city>Tübingen</city>
        <zip>D-72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medica Pro Familia Krakow</name>
      <address>
        <city>Krakow</city>
        <zip>30-002</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Urologiczne Sp. z o.o.</name>
      <address>
        <city>Mysłowice</city>
        <zip>41-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centralny Szpital Kliniczny MSWiA, Klinika Onkologii I Hematologii</name>
      <address>
        <city>Warsaw</city>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Sw. Elżbiety - Mokotowskie Centrum Medyczne</name>
      <address>
        <city>Warsaw</city>
        <zip>02-616</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut M. Curie-Skłodowskiej Centrum Onkologii</name>
      <address>
        <city>Warsaw</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Magodent, Centrum Medyczne Ostrobramska, Oncologii Klinicznej i Chemíoterapii</name>
      <address>
        <city>Warsaw</city>
        <zip>04-125</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Profesorskie Centrum Medyczne OPTIMUM Wrocław</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-421</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki, Katedra i Klinika Urologii i Onkologii Urologicznej</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-556</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Madrid Norte Sanchinarro Centro Integral Oncológico Clara Campal (CIOCC)</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Virgen de la Victoria Campus Universitario de Teatinos s/n</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Universitaria de Navarra Departamento de Oncología</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario Santiago Departamento de Oncología</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15703</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano de Oncología Unidad de Investigación Clínica</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Sahlgrenska Universitetssjukhuset Urologmottagningen</name>
      <address>
        <city>Gothenburg</city>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skånes Universitetssjukhus Malmö Urologmottagningen</name>
      <address>
        <city>Malmö</city>
        <zip>20502</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset Solna Urologiska kliniken</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akademiska sjukhuset Urologmottagningen</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitetssjukhuset Örebro Urologmottagningen</name>
      <address>
        <city>Örebro</city>
        <zip>70185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Basel Medizinische Onkologie</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubünden Department Innere Medizin Hämatologie und Onkologie</name>
      <address>
        <city>Chur</city>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUV Centre Pluridisciplinaire d'Oncologie</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen Department Innere Medizin Hämatologie Medizinische Onkologie</name>
      <address>
        <city>St. Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW32QC</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham City Hospital Department of Oncology</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clatterbridge Cancer Centre</name>
      <address>
        <city>Wirral, Merseyside</city>
        <zip>CH63 4JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>York Hospital</name>
      <address>
        <city>York</city>
        <zip>Y03 8HE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.curevac.de</url>
    <description>Click here for more information about CureVac</description>
  </link>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2013</study_first_submitted>
  <study_first_submitted_qc>March 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2013</study_first_posted>
  <last_update_submitted>February 15, 2017</last_update_submitted>
  <last_update_submitted_qc>February 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic</keyword>
  <keyword>Castrate-refractory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

